John D'Amelio Jr.

Specialty / focus. John D'Amelio Jr.'s only tracked appearance places him on the technology side of in-vitro diagnostics and life-sciences patents. The matter involves Fujirebio Diagnostics' Lumipulse immunoassay platform — automated analyzers and single-use reagent cartridges used for blood-based Alzheimer's disease testing (pTau217/β-amyloid plasma assays). Web searches surfaced no independent practice description or technical focus statement for him, so characterization beyond this single matter should be treated cautiously.

Side preference and role. His one tracked appearance is as plaintiff-side in-house counsel — a 1-0 plaintiff count with no defendant appearances. He represents Fujirebio Diagnostics, Inc., the Malvern, PA-based U.S. operating subsidiary of Japan's Fujirebio Holdings/H.U. Group Holdings. This is an operating-company IP posture (declaratory-judgment plaintiff and IPR petitioner), not NPE/PAE enforcement. With a single data point, no broader side-preference pattern can be inferred.

Firm context. D'Amelio is in-house counsel at Fujirebio Diagnostics, Inc. No prior law-firm history, other employers, or additional matters were verifiable from available sources; multiple attorneys share the surname, and no professional bio surfaced in the searches performed, so I could not confirm his career trajectory beyond the in-house role reflected in the case record.

Notable case and PTAB activity. The tracked matter is Fujirebio Diagnostics, Inc. v. Quanterix Corp., No. 1:25-cv-00659 (D. Del., filed May 28, 2025), in which Fujirebio sought a declaratory judgment of non-infringement of Quanterix's U.S. Patent No. 11,275,092, and Quanterix counterclaimed for infringement against Fujirebio Diagnostics and sister entity Fujirebio Europe N.V. The case is ongoing (motions to dismiss were pending as of late 2025), so no verdict or settlement is available. Fujirebio also petitioned for IPR of the '092 patent (IPR2025-01060); the PTAB denied institution via discretionary denial on October 17, 2025. That single petition does not indicate regular IPR/PGR practice.

Bar / education. Not reliably sourced — omitted.